Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 1998

View Archived Issues

Novel flavonoid derivative SU-840 with potent gastroprotective and ulcer-healing effects

Treatment with recombinant IL-1 receptor safe in HIV-infected patients

OPC-14117: tolerability and safety as antioxidant therapy for Huntington's disease

HIV protease inhibitors developed by research group at Sankyo

Blockade of angiotensin II receptor reduces radiation-induced renal and lung injury

Zeneca forms new subsidiary in Taiwan

Unigene and Warner-Lambert accelerate development of oral calcitonin product

Genta and NCI to collaborate on G-3139 development

Granocyte granted expanded marketing authorization

U.S. patent issues for second product in PathoGenesis' pipeline

Novel antitumor agent discovered by Banyu

Taisho claims potent and selective D4 receptor antagonists

Carcinostatic agents developed at Toagosei

ACAT inhibitors from SS Pharm. for atherosclerosis

Investigation at Kowa results in development of potent CysLT1 receptor antagonists

Series of MMP and TACE inhibitors patented by American Cyanamid

GRP antagonist inhibits pancreatic carcinoma growth in vitro and in vivo

New antimigraine option now available in Canada

Ganaxolone study results presented at AASH meeting

Sankyo overseas clinical pipeline

CNS-selective effects of synthetic, nonfeminizing estrogens

Immunex and American Home Products restructure collaboration

Pasteur Merieux Connaught's AIDS vaccine pipeline in review

Nonsteroidal antiestrogen EM-800 shows potential in breast cancer, osteoporosis

Phase I/II trial of gene therapy to treat peripheral vascular disease

BTG offers paclitaxel analogues for licensing

Phase Ia clinical trial with NIF for ischemic stroke completed by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...